Status:
COMPLETED
Effect of the Use of Continuous Glucose Monitoring Versus Standard Glycemic Control in Hospitalized Patients with Type 2 Diabetes.
Lead Sponsor:
Hospital General Universitario Gregorio Marañon
Conditions:
Diabetes Mellitus Type 2
Hospitalization
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Type 2 diabetes (T2D) is a common pathology in hospitalized patients and is associated with multiple comorbidities. Moreover, it is widely known that glycemic excursions increase hospital stay, infect...
Detailed Description
Over the past few decades advances in diabetes technology have revolutionized patient care and metabolic control. The use of CGM has demonstrated substantial benefits on glycemic control in ambulatory...
Eligibility Criteria
Inclusion
- Over 18 years old
- Admitted to medical or surgical wards with an expected hospitalization duration of more than 72 hours
- Requiring basal-bolus insulin therapy during hospitalization.
Exclusion
- Pregnant women
- Severe mental illnesses
- Chronic use of high doses of ascorbic acid (equivalent to more than 500mg/day)
- Patients hospitalized in Intensive Care Units
- Severe cognitive impairment
- Prior outpatient CGM use
- Refusal of informed consent
- Patients on prolonged absolute diets or receiving artificial nutrition
Key Trial Info
Start Date :
January 10 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 30 2024
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06607224
Start Date
January 10 2022
End Date
January 30 2024
Last Update
September 23 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital General Universitario Gregorio Marañón
Madrid, Madrid, Spain, 28007